DGAP-Adhoc: Dr. Lutz Helmke appointed as new director at Eckert & Ziegler Strahlen- und Medizintechnik AG; Dr. André Heß retires from director's position


 
DGAP-Ad-hoc: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Change of Personnel Dr. Lutz Helmke appointed as new director at Eckert & Ziegler Strahlen- und Medizintechnik AG; Dr. André Heß retires from director's position 31-Aug-2018 / 20:44 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Berlin, 31 August 2018. Today, the Supervisory Board of Eckert & Ziegler Strahlen- und Medizintechnik AG appointed Dr. Lutz Helmke as a new member of the Board of Directors of Eckert & Ziegler Strahlen- und Medizintechnik AG effective September 17, 2018. Dr. Helmke takes over as member of the Board of Directors, filling the position of the former director Dr. André Heß, whose appointment the Supervisory Board revokes effective immediately. The Supervisory Board of Eckert & Ziegler Strahlen- und Medizintechnik AG and Dr. Helmke agreed on a director's contract with terms of office until December 31, 2021. Contact: Eckert & Ziegler Strahlen- und Medizintechnik AG Karolin Riehle Investor Relations Robert-Rössle-Str. 10 13125 Berlin - Germany Tel.: +49-30-94 10 84 138 Tel.: +49-30-94 10 84 112 E-mail: karolin.riehle@ezag.de --------------------------------------------------------------------------- Information and Explanation of the Issuer to this News: Dr. Helmke will manage Eckert & Ziegler Strahlen- und Medizintechnik AG together with Dr. Andreas Eckert as the chairman of the Board of Directors and Dr. Harald Hasselmann as additional director. Dr. Helmke, born in 1961, studied Mathematics and Chemistry at FU Berlin. After graduating from Radio Chemistry studies and receiving his PhD, he switched to Medical Technology and started his career in the marketing department of Biotronik. After that, he held various management positions at Abbott, St. Jude Medical, and most recently MagForce over a period of 25 years. As the head of various task forces within the German Federal Association for Medical Technology, Dr. Helmke also gained a wide range of experience in market launches and the reimbursement aspects of medical products. Dr. Helmke has three children and lives with his family in Berlin-Charlottenburg. --------------------------------------------------------------------------- 31-Aug-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Eckert & Ziegler Strahlenund Medizintechnik AG Robert-Rössle-Str.10 13125 Berlin Germany Phone: 49 30 941084-138 Fax: 49 30 941084-112 E-mail: karolin.riehle@ezag.de Internet: www.ezag.de ISIN: DE0005659700 WKN: 565970 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of Announcement DGAP News Service --------------------------------------------------------------------------- 719779 31-Aug-2018 CET/CEST


Die wichtigsten Finanzdaten auf einen Blick
  2012 2013 2014 2015 2016 2017 2018 2019e
Umsatzerlöse1 120,00 117,14 127,26 139,75 137,94 138,63 168,71 180,00
EBITDA1,2 27,48 22,07 20,10 26,98 24,97 26,62 32,14 32,30
EBITDA-Marge3 22,90 18,84 15,79 19,31 18,10 19,20 19,05 17,94
EBIT1,4 19,73 12,82 12,96 18,22 16,23 17,97 23,39 23,50
EBIT-Marge5 16,44 10,94 10,18 13,04 11,77 12,96 13,86 13,06
Jahresüberschuss1 10,29 9,09 6,50 10,37 9,79 15,12 16,89 19,00
Netto-Marge6 8,58 7,76 5,11 7,42 7,10 10,91 10,01 10,56
Cashflow1,7 16,57 14,65 10,65 16,23 19,83 26,83 21,21 22,50
Ergebnis je Aktie8 1,95 1,72 1,28 2.03 1,81 2,78 3,12 4,10
Dividende8 0,60 0,60 0,60 0,60 0,66 0,80 1,20 1,40
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2018 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: BDO

INVESTOR-INFORMATIONEN
©boersengefluester.de
Eckert & Ziegler
WKN Kurs in € Einschätzung Börsenwert in Mio. €
565970 180,000 Halten 952,74
KGV 2020e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
42,86 17,06 2,568 90,00
KBV KCV KUV EV/EBITDA
7,33 44,92 5,65 28,377
Dividende '19 in € Dividende '20e in € Div.-Rendite '19e
in %
Hauptversammlung
1,40 1,40 0,78 17.06.2020
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
12.05.2020 13.08.2020 12.11.2019 31.03.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
6,53% 42,56% 191,73% 171,90%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Eckert & Ziegler Strahlen- und Medizintechnik AG  ISIN: DE0005659700 können Sie bei DGAP abrufen

Medtech , 565970 , EUZ , XETR:EUZ